NCT07769840Not yet recruiting

Rowing and Cycling Reduce Inflammation in Early-Stage Type 2 Diabetes

Effects of Different Modes of Rowing Combined With Cycling Exercise on Inflammatory Markers in Newly Diagnosed Type 2 Diabetes Patients

Source: ClinicalTrials.gov · Last updated 18 Aug 2026

Brief summary (registry, in English)

This multicenter randomized controlled trial evaluates the short-term (7-day) effects of different rowing-cycling exercise regimens on postprandial glycemic excursions in newly diagnosed type 2 diabetes patients (aged 18-60 years, diagnosis ≤12 months, drug-naïve). A total of 120 participants will be randomized into five groups: control, moderate-intensity continuous cycling, high-intensity interval rowing, and standard combined exercise (rowing + cycling, 50 min). The primary outcome is inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-1ra, IL-10, hs-CRP), body Composition and functional Indicators. Secondary outcomes include change in continuous glucose monitoring-derived glycemic variability (CONGA), and time-in-range. Mixed-effects models will quantify dose-response relationships and identify key effect modifiers (e.g., age). This study aims to establish an evidence-based precision exercise prescription for early-stage type 2 diabetes management.

Status (registry): Not yet recruiting
Study type: Interventional
Enrollment: 120 (estimated)
First submitted: 1 Aug 2026
Start date: 1 Oct 2026
Primary completion date: 10 Oct 2028
Lead sponsor: The 95th Hospital of Putian，Putian, Fujian, China
Diseases: Type 2 diabetes
NCT number: NCT07769840

What you commit to

Study type: Interventional
Planned participants: 120
From 1 Oct 2026 to the primary completion date, 10 Oct 2028
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Type 1 diabetes, gestational diabetes, or other special types of diabetes;
Severe cardiovascular or cerebrovascular diseases (NYHA heart function ≥III, recent myocardial infarction or unstable angina);
Uncontrolled hypertension (resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
Mental illness or cognitive impairment that prevents compliance with the study;
Stress events such as infection, trauma, or surgery in the past month;
Musculoskeletal diseases of the upper or lower limbs that affect rowing machine or bicycle exercise.

Lab values

Severe liver or kidney dysfunction (ALT/AST ≥3 times the upper limit of normal, or eGFR\<60 mL/min/1.73m²);

Other

Severe diabetic complications (such as proliferative retinopathy, severe neuropathy, diabetic foot);
Pregnant or breastfeeding women;
Participation in other interventional clinical studies;

Who the study is looking for

Age between 18-60 years, no gender limited;
Meeting the WHO 1999 diagnostic criteria for T2DM, with a diagnosis time ≤12 months;
Not having received hypoglycemic drug treatment (or only lifestyle intervention, and stopped medication ≥4 weeks before enrollment);
Fasting blood glucose 7.0-13.9 mmol/L, glycated hemoglobin (HbA1c) 6.5%-10.0%;
No regular exercise in the past 3 months (less than 2 times per week of moderate or higher intensity exercise, each \<30 minutes);
Voluntarily signing the informed consent form.

Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
The Ethics Committee of Putian 95 Hospital Coordinator of this site? Confirm its status	Putian	China	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.